ConcizuTrace ELISA
Quantitative ELISA that measures concizumab-mtci levels in citrated plasma from hemophilia A and B patients to support dose adjustment of non-factor replacement prophylaxis.
Casandra.ai provides a unified ordering experience so you can request this test directly from the performing lab, without changing your workflow.
Ordering is available where Casandra has an active integration with the performing lab. Labs that offer this test can connect with us to enable digital ordering.
About this test
ConcizuTrace ELISA is an FDA-authorized, manual enzyme-linked immunosorbent assay that quantitatively measures concizumab-mtci concentration in 3.2% citrated plasma from patients with hemophilia A or B after at least 4 weeks of therapy. Results are used to assess drug exposure and support dose adjustment decisions for non-factor replacement prophylaxis in line with the concizumab prescribing information.
Where this test fits
| Indication | Biomarker | Biomarker details | Therapy (Select a therapy to open its FDA-approved testing pathway) |
|---|---|---|---|
| Hemophilia A patients with or without factor VIII inhibitors and Hemophilia B patients with or without IX inhibitors | Concizumab | Tissue factor pathway inhibitor antagonist | ALHEMO |
IVD Manufacturer
Randox is a global leader in healthcare diagnostics, committed to improving health worldwide through innovative diagnostic solutions. With a focus on quality and precision, Randox Laboratories continues to push the boundaries of diagnostic technology, delivering cutting-edge products that enhance laboratory efficiency and patient care.
Order this test
If your organization is connected to Casandra, you can place an electronic order forConcizuTrace ELISA directly from your existing workflow.
Casandra connects providers, labs, and sponsored programs so that companion diagnostics can be ordered consistently and documented cleanly, regardless of which system you start from.